GuruFocus.comCRISPR helps find new genetic suspects behind ALS/FTDScience DailyThese repeats produce potentially toxic RNA and protein molecules that kill neurons resulting in problems with movement and eventually paralysis for ALS patients and languag… Continue reading
National Institutes of Health (press release)CRISPR helps find new genetic suspects behind ALS/FTD | National …National Institutes of Health (press release)Study provides roadmap for using CRISPR to investigate neurological disorders.CRISPR helps fin… Continue reading
EurekAlert (press release)CRISPR helps find new genetic suspects behind ALS/FTDEurekAlert (press release)These repeats produce potentially toxic RNA and protein molecules that kill neurons resulting in problems with movement and eventually paralysis fo… Continue reading
Experimental Hydrogel Delivers Targeted Chemotherapy, ImmunotherapySpecialty Pharmacy TimesA novel injectable gel scaffold was able to deliver a combination of chemotherapy and immunotherapy to tumors in a sequential fashion, according to a study publi… Continue reading
NasdaqDanaher Expands in Genetics with Integrated DNA TechnologiesNasdaqIDT deals in consumables for genomics applications in molecular biology, qPCR, next-generation sequencing (NGS), gene editing, synthetic biology and molecular diagnostics. Primaril… Continue reading
Cell and gene therapy research boost for NHS Wales teamBBC NewsIt is hoped patients in Wales will get far quicker access to cutting edge treatment and medicines, thanks to a £7m funding boost. A consortium, including NHS Wales, aims to improve how cell… Continue reading
BBC NewsCell and gene therapy research boost for NHS Wales teamBBC NewsIt is hoped patients in Wales will get far quicker access to cutting edge treatment and medicines, thanks to a £7m funding boost. A consortium, including NHS Wales, aims to improve … Continue reading
Lupus News Today |
Phase 2b Trial of Neovacs’ Investigational Lupus Immunotherapy on Track to Conclude in 2018
Lupus News Today A Phase 2b clinical trial assessing Neovacs’ investigational immunotherapy for the treatment of systemic lupus erythematosus (SLE) is on schedule to deliver results by mid-2018, the company recently said. The announcement follows an independent review … |